X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs MERCK LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA MERCK LTD ABBOTT INDIA/
MERCK LTD
 
P/E (TTM) x 44.5 34.2 130.2% View Chart
P/BV x 11.1 3.8 290.5% View Chart
Dividend Yield % 0.6 0.7 81.7%  

Financials

 ABBOTT INDIA   MERCK LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
MERCK LTD
Dec-16
ABBOTT INDIA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs6,0151,060 567.5%   
Low Rs3,707623 595.0%   
Sales per share (Unadj.) Rs1,236.9632.4 195.6%  
Earnings per share (Unadj.) Rs122.245.7 267.3%  
Cash flow per share (Unadj.) Rs129.062.3 207.0%  
Dividends per share (Unadj.) Rs35.0011.00 318.2%  
Dividend yield (eoy) %0.71.3 55.1%  
Book value per share (Unadj.) Rs521.2388.8 134.1%  
Shares outstanding (eoy) m21.2516.60 128.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.91.3 295.4%   
Avg P/E ratio x39.818.4 216.1%  
P/CF ratio (eoy) x37.713.5 279.1%  
Price / Book Value ratio x9.32.2 430.9%  
Dividend payout %28.624.1 119.1%   
Avg Mkt Cap Rs m103,29613,969 739.5%   
No. of employees `0003.01.6 186.7%   
Total wages/salary Rs m3,3701,487 226.7%   
Avg. sales/employee Rs Th8,891.86,631.9 134.1%   
Avg. wages/employee Rs Th1,140.0939.2 121.4%   
Avg. net profit/employee Rs Th878.3479.4 183.2%   
INCOME DATA
Net Sales Rs m26,28410,498 250.4%  
Other income Rs m504242 208.1%   
Total revenues Rs m26,78910,741 249.4%   
Gross profit Rs m3,6651,135 322.9%  
Depreciation Rs m144276 52.4%   
Interest Rs m80-   
Profit before tax Rs m4,0171,102 364.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,421343 413.9%   
Profit after tax Rs m2,596759 342.1%  
Gross profit margin %13.910.8 129.0%  
Effective tax rate %35.431.1 113.6%   
Net profit margin %9.97.2 136.6%  
BALANCE SHEET DATA
Current assets Rs m14,4466,410 225.4%   
Current liabilities Rs m4,7258,828 53.5%   
Net working cap to sales %37.0-23.0 -160.5%  
Current ratio x3.10.7 421.1%  
Inventory Days Days5158 89.1%  
Debtors Days Days2038 50.9%  
Net fixed assets Rs m1,1131,406 79.1%   
Share capital Rs m213166 128.0%   
"Free" reserves Rs m10,8086,286 171.9%   
Net worth Rs m11,0766,455 171.6%   
Long term debt Rs m00-   
Total assets Rs m16,2418,828 184.0%  
Interest coverage x497.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.61.2 136.1%   
Return on assets %16.08.6 186.6%  
Return on equity %23.411.8 199.4%  
Return on capital %36.317.1 212.8%  
Exports to sales %0.68.3 7.4%   
Imports to sales %12.621.0 60.1%   
Exports (fob) Rs m162869 18.6%   
Imports (cif) Rs m3,3222,209 150.4%   
Fx inflow Rs m268959 28.0%   
Fx outflow Rs m3,9272,612 150.4%   
Net fx Rs m-3,659-1,653 221.4%   
CASH FLOW
From Operations Rs m2,5141,070 234.9%  
From Investments Rs m-800-750 106.6%  
From Financial Activity Rs m-803-150 536.0%  
Net Cashflow Rs m912171 533.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 7.9 18.2 43.4%  
FIIs % 0.1 1.0 10.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 29.1 58.8%  
Shareholders   18,270 28,591 63.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - SUN PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS